Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | MAP2K1 | Q02750 | 14/20 | 0.47 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1615190 | 0.90 | KCNH2 (0.81) | KCNH2CYP2C9MAP2K1MAP2K2CYP2C19 | |
| SCHEMBL1615478 | 0.89 | KCNH2 (0.80) | KCNH2CYP2C9MAP2K1MAP2K2ABCB11 | |
| SCHEMBL29684045 | 0.89 | KCNH2 (0.80) | KCNH2CYP2C9MAP2K1MAP2K2ABCB11 | |
| SCHEMBL1614846 | 0.88 | KCNH2 (0.65) | KCNH2CYP2C9MAP2K1MAP2K2ABCB11 | |
| SCHEMBL1615623 | 0.87 | KCNH2 (0.62) | KCNH2CYP2C9MAP2K1MAP2K2ABCB11 | |
| SCHEMBL1615842 | 0.87 | KCNH2 (0.61) | KCNH2CYP2C9MAP2K1MAP2K2CYP2C19 | |
| SCHEMBL1616128 | 0.83 | KCNH2 (0.63) | KCNH2CYP2C9MAP2K1MAP2K2ABCB11 | |
| SCHEMBL29683678 | 0.83 | KCNH2 (0.63) | KCNH2CYP2C9MAP2K1MAP2K2ABCB11 | |
| SCHEMBL391436 | 0.80 | MAP2K1 (0.55) | MAP2K1MAP2K2ABCB11NQO2 | |
| SCHEMBL21553375 | 0.80 | KCNH2 (0.55) | KCNH2CYP2C9MAP2K1MAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9206174-B2 | 5-anilinoimidazopyridines and methods of use | GENENTECH, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| EP-2690101-A1 | 5-Anilinoimidazopyridines and Methods of Use | Genentech, Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| EP-2222675-B1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH INC (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20130150584-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20120309765-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-8288408-B2 | 5-anilinoimidazopyridines and methods of use | GENENTECH, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20110158990-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7923456-B2 | 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase | GENENTECH, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923456-B2 | 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase | GENENTECH, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923456-B2 | 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase | GENENTECH, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| WO-2009085983-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309765-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, PCNA, TYMP | KCNH2 2040/4885CYP2C9 3917/4885MAP2K1 999/4885 |
| US-20110158990-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, PCNA, TYMP | KCNH2 2040/4885CYP2C9 3917/4885MAP2K1 999/4885 |
| US-20100004269-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, MAP3K5, MAPKAPK5 | KCNH2 1382/4885CYP2C9 2665/4885MAP2K1 64/4885 |
| US-20130150584-A1 | 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE | MKI67, PCNA, TYMP | KCNH2 2040/4885CYP2C9 3917/4885MAP2K1 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.